Details for Patent: 9,427,578

Title:	Pharmacokinetics of iontophoretic sumatriptan administration
Abstract:	Improved pharmacokinetic profiles for the iontophoretic delivery of sumatriptan are described.
Inventor(s):	Sebree; Terri B. (Gladwyne, PA), Pierce; Mark (Essex, CT), O'neill; Carol (Phoenixville, PA)
Assignee:	Teva Pharmaceuticals International GmbH (Rapperswil-Jona, CH)
Filing Date:	Feb 20, 2014
Application Number:	14/185,485
Claims:	1. A method for treating a sumatriptan responsive state in a human in need thereof, comprising iontophoretically delivering to said human an effective amount of sumatriptan, or a salt thereof, using a current of 4 mA or greater during a first portion of a treatment period for about one hour without substantially irritating said human's skin, such that said sumatriptan responsive state in said human is treated. 2. The method of claim 1, wherein an effective amount of the sumatriptan, or the salt thereof, delivered systemically is greater than 5 mg. 3. The method of claim 1, wherein the sumatriptan, or salt thereof, is sumatriptan succinate. 4. The method of claim 1, wherein the method further comprises iontophoretically administering to said human an effective amount of sumatriptan, or a salt thereof, using a current of 2 mA during a second portion of the treatment period. 5. The method of claim 4, wherein the effective amount of sumatriptan, or salt thereof, delivered systemically to said human is greater than 5 mg. 6. The method of claim 5, wherein the sumatriptan, or salt thereof, is sumatriptan succinate. 7. The method of claim 6, wherein the sumatriptan responsive state is migraine. 8. An iontophoretic patch designed to iontophoretically deliver to a human sumatriptan, or a salt thereof, using a current of 4 mA or greater during a first treatment period for about one hour, without substantially irritating said human's skin. 9. The patch of claim 8, wherein the patch systemically delivers greater than 5 mg of sumatriptan or salt thereof. 10. The patch of claim 8, wherein the sumatriptan, or salt thereof, is sumatriptan succinate. 11. The patch of claim 8, wherein the patch is further designed to iontophoretically deliver sumatriptan, or a salt thereof, using a current of 2 mA during a second treatment period. 12. The patch of claim 11, wherein an amount of sumatriptan, or the salt thereof, delivered systemically to said human is greater than 5 mg. 13. The patch of claim 12, wherein the sumatriptan, or salt thereof, is sumatriptan succinate.